Nick Andrews

1992–2026 年に発表

287
論文数
43,920
被引用数
106
h 指数
269
i10 指数

被引用数

Nick Andrews の年別被引用数1897 年: 被引用 1 件1911 年: 被引用 1 件1982 年: 被引用 3 件1989 年: 被引用 1 件1990 年: 被引用 2 件1991 年: 被引用 1 件1993 年: 被引用 5 件1994 年: 被引用 3 件1995 年: 被引用 4 件1996 年: 被引用 9 件1997 年: 被引用 17 件1998 年: 被引用 20 件1999 年: 被引用 27 件2000 年: 被引用 32 件2001 年: 被引用 34 件2002 年: 被引用 62 件2003 年: 被引用 84 件2004 年: 被引用 72 件2005 年: 被引用 96 件2006 年: 被引用 106 件2007 年: 被引用 94 件2008 年: 被引用 110 件2009 年: 被引用 117 件2010 年: 被引用 156 件2011 年: 被引用 135 件2012 年: 被引用 115 件2013 年: 被引用 158 件2014 年: 被引用 124 件2015 年: 被引用 169 件2016 年: 被引用 176 件2017 年: 被引用 194 件2018 年: 被引用 145 件2019 年: 被引用 707 件2020 年: 被引用 882 件2021 年: 被引用 2,312 件2022 年: 被引用 3,282 件2023 年: 被引用 1,535 件2024 年: 被引用 1,530 件2025 年: 被引用 531 件2026 年: 被引用 25 件1898〜1910 年は被引用が無いため表示していません1912〜1981 年は被引用が無いため表示していません1983〜1988 年は被引用が無いため表示していません1992 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,415 件、この内訳の 19.7%イギリス: 引用元論文 2,264 件、この内訳の 13%中国: 引用元論文 867 件、この内訳の 5%ドイツ: 引用元論文 724 件、この内訳の 4.2%カナダ: 引用元論文 656 件、この内訳の 3.8%オーストラリア: 引用元論文 598 件、この内訳の 3.4%イタリア: 引用元論文 580 件、この内訳の 3.3%フランス: 引用元論文 559 件、この内訳の 3.2%スペイン: 引用元論文 468 件、この内訳の 2.7%オランダ: 引用元論文 450 件、この内訳の 2.6%スイス: 引用元論文 385 件、この内訳の 2.2%インド: 引用元論文 340 件、この内訳の 2%
0%19.7%その他 34.9%

分野

  • Medicine70%
  • Immunology and Microbiology10%
  • Biochemistry, Genetics and Molecular Biology4.7%
  • Neuroscience3.6%
  • Mathematics3.5%
  • Social Sciences3.2%
  • その他5%

トピック

  • SARS-CoV-2 and COVID-19 Research13.5%
  • COVID-19 Clinical Research Studies7.1%
  • Vaccine Coverage and Hesitancy5.6%
  • Pneumonia and Respiratory Infections4.3%
  • Respiratory viral infections research4.1%
  • COVID-19 epidemiological studies4%
  • その他61.4%

共著者

全論文

検索で開く
  1. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jamie Lopez Bernal - New England Journal of Medicine 2022 被引用: 2,240

  2. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Samir Bhatt, Paula Blomquist, Asad Zaidi, Erik Volz, Nurin Abdul Aziz, Katie Harman, Sebastian Funk, Sam Abbott, Russell Hope, Andre Charlett, Meera Chand, Azra C Ghani, Shaun R Seaman, Gavin Dabrera, Daniela De Angelis, Anne M Presanis, Simon Thelwall, Russell Hope, Andre Charlett, Meera Chand, Azra C Ghani, Shaun R Seaman, Gavin Dabrera, Daniela De Angelis, Anne M Presanis, Simon Thelwall - The Lancet 2022 被引用: 1,294

  3. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - 2022 被引用: 1,226

  4. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 3,080

  5. Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study

    著者: , , , , , , , , , , , , , , , , , - The Lancet Infectious Diseases 2023 被引用: 158

  6. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 676

  7. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon C. Robson, Ari Waisman, Nick Andrews, Michael Costigan, Keith M. Channon, Günter Weiß, Andrey V. Kozlov, Mark Tebbe, Kai Johnsson, Clifford J. Woolf, Josef Penninger - Nature 2018 被引用: 287

  8. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

    著者: , , , , , , , , , , , , , , - BMJ 2021 被引用: 1,395

  9. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

    著者: , , , , , , , , , - The Lancet Infectious Diseases 2014 被引用: 545

  10. Does age matter? The impact of rodent age on study outcomes

    著者: , , , , , , , , , , , , , , , - Laboratory Animals 2016 被引用: 368

  11. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel R Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Jo Salkeld, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Ann Sturdy, Emma C Thomson, Shirley Todd, Chris Twelves, Robert C Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Xinxue Liu, Saul N Faust, Andrew Riordan, Andrew Ustianowski, Chris A Rogers, Stephen Hughes, Laura Longshaw, Jane Stockport, Rachel Hughes, Lynne Grundy, Lona Tudor Jones, Arpan Guha, Emma Snashall, Tom Eadsforth, Sally Reeder, Kim Storton, Malathi Munusamy, Bridget Tandy, Akamino Egbo, Stephen Cox, Nabeela Nazir Ahmed, Anil Shenoy, Rachel Bousfield, Donna Wixted, Helen Gutteridge, Becky Mansfield, Christopher Herbert, Kyra Holliday, James Calderwood, Dominique Barker, Jacqueline Brandon, Hayley Tulloch, Suzie Colquhoun, Helen Thorp, Helen Radford, Julie Evans, Helena Baker, Jeanette Thorpe, Sally Batham, Jessica Hailstone, Rachael Phillips, Dileep Kumar, Fran Westwell, Fiona Makia, NinaSimone Hopkins, Lara Barcella, Mushiya Mpelembue, Maja dabagh ほか 208 名 - The Lancet 2021 被引用: 685

  12. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

    著者: , , , , , , , - Nature Medicine 2022 被引用: 381

  13. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study

    著者: , , , , , , , - The Lancet Infectious Diseases 2024 被引用: 123

  14. Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment

    著者: , , - Neuron 2019 被引用: 236

  15. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study

    著者: , , , , - The Lancet Infectious Diseases 2023 被引用: 64

  16. Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis

    著者: , , , , , , - The Lancet Infectious Diseases 2022 被引用: 264

  17. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rostam Osanlou, DR Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Emma C. Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S Nguyen-Van-Tam, Matthew D. Snape, Xinxue Liu, Saul N. Faust, Alasdair Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L. Goodman, Christopher Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Nasir Kanji, Vincenzo Libri, Martin Llewelyn, Alastair McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama F Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, DR Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Tanveer Bawa, Dinesh Saralaya, Sunil Sharma, Ray Sheridan, Mina Maallah, Emma C. Thomson, Shirley Todd, Chris Twelves ほか 264 名 - The Lancet Infectious Diseases 2022 被引用: 177

  18. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , MA Chand, André Charlett, Harriet Crawford, Michelle Cole, John B. Conneely, Silvia D’Arcangelo, Joanna Ellis, Simon Evans, Sarah Foulkes, Natalie Gillson, Robin Gopal, Laura Lee Hall, VJ Hall, Pauline Harrington, Susan Hopkins, Jacqueline Hewson, Katja Höschler, Dean Ironmonger, Jasmin Islam, Meaghan Kall, Ioannis Karagiannis, O Kay, Jameel Khawam, E King, Peter Kirwan, Robert Kyffin, Angie Lackenby, M Lattimore, Ezra Linley, Jamie Lopez Bernal, Lesley Mabey, Reuben McGregor, Shahjahan Miah, EJM Monk, Katie Munro, Z Naheed, A Nissr, AM O'Connell, Blanché Oguti, H.U. Okafor, S Organ, J Osbourne, Ashley Otter, Monika Patel, Steven G. Platt, Diane Pople, Kyle Potts, Mary Ramsay, Julie V. Robotham, Sakib Rokadiya, C Rowe, Ayoub Saei, G Sebbage, Amanda Semper, Madhumita Shrotri, Ruth Simmons, A Soriano, P Staves, Sean C. Taylor, Adam Taylor, A Tengbe, Simon Tonge, Amoolya Vusirikala, Sarah Wallace, Elizabeth M. H. Wellington, Maria Zambon, Diane Corrigan, Muhammad Sartaj, Lisa Cromey, Sean Campbell ほか 231 名 - The Lancet 2021 被引用: 738

  19. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study

    著者: , , , , - Nature Communications 2022 被引用: 170

  20. Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales

    著者: , , , , , , - EClinicalMedicine 2018 被引用: 148

  21. Effectiveness of maternal pertussis vaccination in England: an observational study

    著者: , , , , , , , , - The Lancet 2014 被引用: 734

  22. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study

    著者: , , , , , , - The Lancet Infectious Diseases 2022 被引用: 91

  23. Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Vardeh, Gary A. Walco, Ajay D. Wasan, Ursula Wesselmann - Journal of Pain 2022 被引用: 93

  24. Mechanistic Differences in Neuropathic Pain Modalities Revealed by Correlating Behavior with Global Expression Profiling

    著者: , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2018 被引用: 163